Gaithersburg biotech startup Vtesse Inc. — a company with a goal to commercialize National Institutes of Health rare disease drug candidates — secured $17 million in additional Series A funding, it was announced Monday. The round was led by repeat investors Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates and Pfizer Venture Investments. The funding will be used to expand global clinical trials for its lead drug candidate VTS-270, a medicine…
from http://www.bizjournals.com/baltimore/news/2016/07/25/gaithersburg-rare-disease-startup-vtesse-inc-nabs.html?ana=RSS%26s=article_search
via http://baltimorecheckbook.tumblr.com/post/147955381157
No comments:
Post a Comment